CL2009001290A1 - Imidazo [4,5-b] pyridine derivative compounds, composition and pharmaceutical combination; and use in the treatment of a disorder such as osteoporosis, gingivitis, pain, arthritis, among others. - Google Patents

Imidazo [4,5-b] pyridine derivative compounds, composition and pharmaceutical combination; and use in the treatment of a disorder such as osteoporosis, gingivitis, pain, arthritis, among others.

Info

Publication number
CL2009001290A1
CL2009001290A1 CL2009001290A CL2009001290A CL2009001290A1 CL 2009001290 A1 CL2009001290 A1 CL 2009001290A1 CL 2009001290 A CL2009001290 A CL 2009001290A CL 2009001290 A CL2009001290 A CL 2009001290A CL 2009001290 A1 CL2009001290 A1 CL 2009001290A1
Authority
CL
Chile
Prior art keywords
gingivitis
imidazo
osteoporosis
arthritis
pain
Prior art date
Application number
CL2009001290A
Other languages
Spanish (es)
Inventor
Taracido Ivan Cornella
Edmund Martin Harrington
Rene Hersperger
Rene Lattmann
Wolfgang Miltz
Klaus Weigand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2009001290A1 publication Critical patent/CL2009001290A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos derivados de imidazo[4,5-b]piridina, composición y combinación farmacéutica; y uso en el tratamiento de un trastorno tal como osteoporosis, gingivitis, dolor, artritis, entre otras.Imidazo [4,5-b] pyridine derivative compounds, composition and pharmaceutical combination; and use in the treatment of a disorder such as osteoporosis, gingivitis, pain, arthritis, among others.

CL2009001290A 2008-05-26 2009-05-26 Imidazo [4,5-b] pyridine derivative compounds, composition and pharmaceutical combination; and use in the treatment of a disorder such as osteoporosis, gingivitis, pain, arthritis, among others. CL2009001290A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08156933 2008-05-26

Publications (1)

Publication Number Publication Date
CL2009001290A1 true CL2009001290A1 (en) 2010-09-10

Family

ID=40957737

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001290A CL2009001290A1 (en) 2008-05-26 2009-05-26 Imidazo [4,5-b] pyridine derivative compounds, composition and pharmaceutical combination; and use in the treatment of a disorder such as osteoporosis, gingivitis, pain, arthritis, among others.

Country Status (7)

Country Link
US (1) US20090291942A1 (en)
AR (1) AR071884A1 (en)
CL (1) CL2009001290A1 (en)
PE (1) PE20100143A1 (en)
TW (1) TW201000480A (en)
UY (1) UY31847A (en)
WO (1) WO2009144201A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044731A1 (en) * 2011-01-04 2014-02-13 Robert Nussenblatt Methods of treating age-related macular degeneration
US8748435B2 (en) * 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
EP2900237A1 (en) 2012-09-25 2015-08-05 Novartis AG Compounds for use in gastric complication

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
ES2079315B1 (en) * 1994-02-24 1996-10-16 Uriach & Cia Sa J NEW IMIDAZOPIRIDINES.
DE19546919A1 (en) * 1995-12-15 1997-06-19 Bayer Ag N-heterocyclically substituted phenylacetic acid derivatives
JP4866723B2 (en) * 2004-02-26 2012-02-01 協和発酵キリン株式会社 Preventive and / or therapeutic agent for neutrophilic inflammatory disease

Also Published As

Publication number Publication date
TW201000480A (en) 2010-01-01
UY31847A (en) 2010-01-05
AR071884A1 (en) 2010-07-21
PE20100143A1 (en) 2010-02-23
WO2009144201A1 (en) 2009-12-03
US20090291942A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
CL2011000668A1 (en) Compounds derived from pyrazolopyridine; Preparation process; Pharmaceutical composition and use in the treatment of diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, among others.
CL2008000670A1 (en) Compounds derived from thiazolidinediones and substituted oxazolidinediones; pharmaceutical composition; process of preparation of the pharmaceutical composition; and use in the treatment of diseases such as rheumatoid arthritis, epoc, cancer, among others.
ECSP088425A (en) ACTIVITY INHIBITORS Akt
CL2011000116A1 (en) Compounds derived from imidazo [1,2-a] pyridine; preparation procedure; pharmaceutical composition; intermediate compounds; and use in the treatment of cancer.
CL2007003774A1 (en) COMPOUNDS DERIVED FROM QUINAZOLINA SUBSTITUTES, INHIBITORS OF QUINASA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, ATEROSCLEROSIS AND ARTHRITIS.
CL2009000448A1 (en) Compounds derived from 3-sulfonylamino-n- (1h-pyrazolo- [3,4-b] pyridin-5-yl) benzamide; preparation processes; intermediate compounds; pharmaceutical composition; and use for the treatment of cancer, such as sarcoma, carcinoma, adenoma, among others.
CL2008001540A1 (en) Compounds derived from pyrrolopyridines and pyrazolopyridines; pharmaceutical composition; and use in the treatment of cancer.
CL2007001710A1 (en) Substituted amino-pyrazolopyridine derivatives; Preparation method; pharmaceutical composition; and use in the treatment of diseases such as tumors, rheumatoid arthritis, diseases of deregulated vascular growth, among others.
CL2008001709A1 (en) Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
CL2008001374A1 (en) Compounds derived from pyrazolo pyrimidines, inhibitors of pde9; pharmaceutical composition comprising said compounds; Useful in the treatment of a neurodegenerative and cognitive disorder such as Alzheimer's disease and schizophrenia.
CL2007001711A1 (en) Compounds derived from substituted pyrazolopyridine; pharmaceutical composition comprising them; method of preparation of the compounds, intermediates; and their use in the treatment of diseases, such as tumors, rheumatoid arthritis, diseases of deregulated vascular growth, among others.
CL2008001813A1 (en) COMPOUNDS DERIVED FROM QUINOLIN-3-CARBONITRILE SUBSTITUTED WITH PIPERAZINE; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS ARTHRITIS, INFLAMMATION, CANCER BETWEEN OTHERS (DIV. SOL. 266-04).
BRPI0810064B8 (en) compounds containing tricyclic nitrogen as antibacterial agents, pharmaceutical compositions comprising said compounds and their use for the treatment of bacterial infections in mammals
CL2012000248A1 (en) Insulin conjugated compound; preparation procedure; pharmaceutical composition comprising it; pharmaceutical combination; pharmaceutical kit; use in the treatment of insulin-mediated disorders.
CL2011001427A1 (en) Compounds derived from 4-azetidinyl-1-heteroaryl-cyclohexanol; pharmaceutical composition; and use in the treatment of diseases such as epoc, atherosclerosis, rheumatoid arthritis, among others.
CL2007002708A1 (en) COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRIDINA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, CAQUEXY, INFLAMMATORY DISORDERS, AMONG OTHERS.
CL2008001745A1 (en) Compounds derived from imidazo [1,2-a] pyrazine; pharmaceutical composition; and use of the compounds as protein kinase inhibitors in the treatment of cancer.
UA107814C2 (en) Spiro-oxindoles antagonists mdm 2
PE20090113A1 (en) TRICYCLIC COMPOUNDS AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR, COMPOSITIONS AND PROCEDURES
CL2008001114A1 (en) Compounds derived from benzimidazole; pharmaceutical composition; and use in the treatment of diseases such as overactive bladder, pain, obesity, seizures, among others.
HN2008001530A (en) AMINO PYRIMIDINE COMPOUNDS 2.6- SUBSTITUTED -4-MONOSUSTITUTED AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEIVER
BR112012017473A2 (en) pyrido (1,2-a) pyrimidines, their use as well as pharmaceutical composition comprising such compounds
CO6690805A2 (en) 6-amino-nicotinamides substituted as modular of kcnq2 / 3
CL2008001373A1 (en) Compounds derived from substituted phenylamino-benzene; Preparation method; pharmaceutical composition; farm kit; and use of said compounds in the treatment of cancer.
ECSP088763A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF DEPRESSION